DAS 181

Drug Profile

DAS 181

Alternative Names: DAS 181-F02; DAS181; DAS181-F04; Fludase; NEX DAS181; ParaDase

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma; NexBio
  • Class Antivirals; Recombinant fusion proteins
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parainfluenza virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections; Parainfluenza virus infections
  • Preclinical Enterovirus infections; Polyomavirus infections
  • Research Metapneumovirus infections; Respiratory syncytial virus infections
  • No development reported Asthma

Most Recent Events

  • 10 Oct 2017 DAS 181 receives Breakthrough Therapy status for Parainfluenza virus infections in USA
  • 10 Oct 2017 DAS 181 is available under expanded access programme for the treatment of Parainfluenza virus infections in USA
  • 10 Oct 2017 Ansun BioPharma plans a phase III trial in Parainfluenza virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top